NextCure is a clinical-stage biopharmaceutical company that develops immunomedicines to treat cancer and immune-related diseases by restoring normal immune function. Its lead product candidate, NC318, is in Phase II clinical trials for advanced or metastatic solid tumors. The company is also developing other immunomedicines, including NC410, NC762, and NC525, which target different molecules and are in various stages of development. NextCure has a license agreement with Yale University and is headquartered in Beltsville, Maryland.